AtriCure (ATRC) Prices Offering

AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems for the treatment of atrial fibrillation, or AF, and systems for the exclusion of the left atrial appendage, today announced the pricing of its previously announced underwritten public offering of 3,475,000 shares of its common stock at a public offering price of $7.25 per share. In connection with the offering, AtriCure has also granted the underwriter a 30-day option to purchase up to an additional 521,250 shares of common stock to cover over-allotments, if any. Piper Jaffray & Co. is acting as the sole manager for the offering.

Net proceeds from the sale of the shares after underwriting discounts and commissions and other offering expenses are expected to be approximately $23.5 million. The offering is subject to customary closing conditions and is expected to close on Tuesday, January 22, 2013.

AtriCure plans to use the net proceeds from the offering for general corporate purposes and working capital.

The offering was made pursuant to a prospectus supplement to AtriCure’s prospectus, dated July 20, 2011, filed as part of AtriCure’s effective $50 million shelf registration statement.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Parabilis Medicines closes $770.5 million IPO and concurrent private placement
• Snow Rothschild Acquisition Corp. closes $200 million IPO
• Class 1 Nickel completes private placement and debt-to-equity conversion